Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development
- TET platform shows efficient T cell priming and beneficial safety profile
- Data supported clinical transition to ongoing TENDU Phase I trial
- TET platform offers potential to strengthen T cell response to cancer cells
Oslo, 8 April 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, presents data on the Tetanus-Epitope Targeting (TET)-platform, the company’s technology for improving tumor-reactive T cell responses via pre-existing tetanus-specific immunity.
The data shows that TET enables the efficient and antigen-specific T cell priming required for an effective vaccine adjuvant system, with no safety concerns. It will be presented as a poster at the annual meeting of the American Association for Cancer Research (AACR) taking place on April 8-13, 2022 in New Orleans, Louisiana (AACR22).
The TET technology makes use of pre-existing anti-tetanus toxoid antibodies – present in anybody vaccinated against tetanus infections – to improve the bioavailability, stability, and immunogenicity of tumor-derived peptide therapeutics. To create the TET-based vaccine used in Ultimovacs’ ongoing TENDU Phase 1 dose escalation study in prostate cancer, four distinct synthetic long peptides derived from prostate tumor associated antigen were conjugated to a core molecule.
The AACR poster describes a number of important elements of the immune response to TET-based conjugates. Tests in a preclinical model demonstrated that a TET-based conjugate enhanced T cell priming in human transgenic HLA-DR4 mice. Recall T cell responses were measurable in human blood in response to the TET-based conjugates.
The data also showed the reassuring safety profile of the TET system. There were no signs of toxicity in preclinical assessments and there was no suggestion of risk of immunotoxicity when studying cytokine release and complement activation.
“We are pleased to present the data supporting the progress to the clinic of our TET technology,” said Carlos de Sousa, Chief Executive Officer of Ultimovacs. “When the results from the TENDU trial are available, the Company will be better positioned to make decisions regarding the next steps in the clinical development of the exciting TET platform.”
The TET platform allows for the production of multiple therapeutic cancer vaccines. It can be used to strengthen and increase T cell responses to cancer cells by targeting antigens that are specific to one type of cancer or common to many tumor types. By combining cancer antigens and the vaccine adjuvant in the same molecule, this TET platform can generate vaccine candidates with a beneficial safety and administration profile, presenting an opportunity to treat patients at an early stage of their disease.
The AACR poster presentation (#4160) is entitled “Promoting immunogencity of synthetic long peptide vaccines based on in vivo IgG complex formation: Preclinical evaluation and clinical entry of the TET platform”
The poster will be presented on Monday April 11, 2022 in New Orleans Convention Center, Exhibit Halls D-H, Poster Section 22, and is available on Ultimovacs' website in the "Presentations and Publications"-section.
The abstract is published in the online Proceedings of the AACR.
About the TET-platform
The Tetanus-Epitope Targeting(TET)-platform offers an approach to strengthen and increase T cell responses against cancer-specific peptides by combining cancer-specific antigens and vaccine adjuvant in the same conjugated molecule, allowing for a beneficial safety profile and simplifying administration. The platform generates new, first-in-class cancer vaccine candidates that harness pre-existing antibody responses resulting from standard tetanus vaccinations. TET vaccine candidates can be tailored to many types of cancer.
The TENDU clinical trial (NCT04701021) is a first-in-human, Phase I study and the first clinical trial of a vaccine from Ultimovacs' Tetanus-Epitope Targeting (TET)-platform. The trial is being conducted at the Oslo University Hospital, Norway, and evaluates the safety of the vaccine in prostate cancer patients who have relapsed after radical prostatectomy. The primary objective of the study is to evaluate the safety and tolerability of three different doses of the vaccine. Patients will receive the vaccine prior to obtaining standard-of-care treatment consisting of radiation and antihormone therapy and will be followed for 6 months after the last dose of the vaccine to assess immunological responses such as the activation of T cells and anti-tumor activity.
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types in combination with other immunotherapies. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Phone: +47 90686815
Mary-Ann Chang, LifeSci Advisors
Phone: +44 7483 284 853
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Cool Company Ltd. – Q1 2022 Business Update call16.5.2022 23:04:27 CEST | Press release
Cool Company Ltd will hold a Q1 2022 business update call for investors at 10am Oslo time on Tuesday May 31. Prior to the start of the call a presentation will be made available in the Investors section of the Cool Company Ltd. website www.coolcoltd.com We recommend that participants join the conference call via the listen-only live webcast link provided. Sell-side analysts interested in raising a question during the Q&A session that will immediately follow the presentation should access the event via the conference call dial-in information below. Please dial in 10 minutes prior to the start time to allow time for call handling. Information on how to ask questions will be given at the beginning of the Q&A session. There will be a limit of two questions per participant. a. Listen-only live webcastlink Go to the Investors section at www.coolcoltd.com and click on the link to "Webcast". To listen to the conference call from the web, you need to have installed Windows Media Player, and you
Golar releases its 2021 Environmental, Social and Governance report16.5.2022 22:53:05 CEST | Press release
Golar LNG Limited (“Golar”) is pleased to announce that it has issued its 2021 Environmental, Social and Governance (“ESG”) report. This comprehensive report describes Golar’s important role in advancing the global energy transition to a lower carbon future - championing LNG as a transition fuel in partnership with renewables, and as a reliable alternative for those in need of energy security today. As part of our target to further reduce emissions from our operations Golar has invested in a carbon capture technology company that has developed and achieved proof of concept for a CO2 capture and separation membrane technology. Subject to successful completion of a commercial pilot project with another industrial user, the technology could be used in future FLNG projects. Our 2021 ESG report is attached and will also be posted to our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934
Inventiva reports 2022 First Quarter Financial Information and provides clinical development update16.5.2022 22:00:00 CEST | Press release
Cash position2 at €80.5m as of March 31, 2022The Group did not generate any revenue in Q1 2022Signature of a €50 million bullet credit facility agreement with the European Investment BankUpdate on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported its cash position as of March 31, 2022 and its revenues for the first quarter of 20221, and provided an update on its clinical programs. Cash Position As of March 31, 2022, Inventiva’s cash position stood at €80.5 million com
ASM INTERNATIONAL N.V. ANNOUNCES VOTING RESULTS OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.5.2022 21:00:00 CEST | Press release
Almere, the Netherlands May 16, 2022 ASM International N.V. (Euronext Amsterdam: ASM) today announces the voting results of its Annual General Meeting of Shareholders held on May 16, 2022, at the Van der Valk Hotel in Almere, the Netherlands. The shareholders approved all resolutions as proposed to the Annual General Meeting of Shareholders. The main approved resolutions include the following: Mr. Hichem M’Saad was appointed as a member of the Management Board and as the CTO. The Remuneration Policy for the Management Board and for the Supervisory Board were approved. Also Mr. Marc de Jong was reappointed as member of the Supervisory Board. Furthermore the financial statements for the year 2021 were adopted, the shareholders discharged the members of the Management Board and Supervisory Board from liability in relation to the exercise of their duties in the financial year 2021, and the shareholders also voted in favor of a regular dividend payment of €2.50 per common share. About ASM I
Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm i samband med apportemission16.5.2022 18:00:00 CEST | Pressemelding
ELECTRA GRUPPEN AB (publ) orgnr. 556065-4054 Pressmeddelande 2022-05-16 Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) offentliggör prospekt avseende upptagande till handel av nyemitterade aktier på Nasdaq Stockholm i samband med apportemission Electra Gruppen AB (publ) (u.ä.t Elon AB (publ)) (”Electra” eller ”Bolaget”), offentliggör idag det prospekt som upprättats inför upptagande till handel av de nyemitterade aktierna på Nasdaq Stockholm med anledning av den apportemission genom vilken Electra förvärvar samtliga aktier i Elon Group AB (”Elon”) (”Transaktionen”). Transaktionen beskrivs närmare i Electras pressmeddelande daterat den 7 december 2021. På Electras årsstämma den 28 mars 2022 bemyndigades styrelsen att besluta om apportemissionen för att genomföra Transaktionen. Den 13 maj 2022 beslutade Electras styrelse om apportemission av 9 659 223 aktier till Elon Group Holding. Prospektet som har upprättats med anledning av upptagande till handel av de nyemitterade aktierna i samb